Efficacy and Safety Evaluation of Caspofungin for Patients with Invasive Fungal Infection and Non-effect/intolerant to Imidazole/polyenoid

Objective: To evaluate the efficacy and safety of caspofungin in patients with invasive fungal infetion(IFI) but non-effect/intolerant to imidazole/polyenoid.Methods: A retrospective analysis was conducted in 16 IFI patients who were non-effect/intolerant to imidazole/polyenoid.They were treated with caspofungin in a dose of 70 mg in the first day,and then in a maintenance dose of 50 or 35 mg·d-1.Results: The treatment was ineffective in the group with a short course of caspofungin(≤7 days),while patients in the group with a long course(≥10 days) had clinical responses.Used as the first-line antifungal therapy,caspofungin demonstrated favorable effects in two cases.Used as a salvage treatment,the improvement rate of caspofungin was 42.9%(6/14).The total efficiency was 50%.No drug-related clinical or laboratory adverse events occurred in the patients received caspofungin.Conclusion: Caspofungin is safe and in certain extent effective,and it may be used as the first choice for IFI patients.